The relationship between alpha-synuclein, Lewy body-like inclusions and nigrostriatal degenerated will be evaluated using transgenic mice in which the human wild-type or mutant (A53T) forms of alpha-synuclein are overexpressed under the tyrosine hydroxylase promoter. The first hypothesis to be tested is that overexpression of human alpha-synuclein itself leads to neurodegenerative changes. Changes in the number o dopaminergic neurons in the substantia nigra, alterations in striatal dopaminergic terminals, and the possible formation of Lewy body-like inclusions will be compared in overexpressing mice vs. controls of different ages. The second hypothesis is that overexpression of alpha-synuclein increases the vulnerability f the nigrostriatal system to neurotoxic injury. Mice will be exposed to MPTP, 6-hydroxydopamine, or methamphetamine, and assessed for cell damage and inclusion body formation in the nigrostriatal system The third hypothesis is that an impairment of proteasome activity play a role in alpha-synuclein aggregation and consequent neurodegeneration. The effects of proteasome inhibition the formation of Lewy body-like inclusions will be compared in mice overexpressing alpha-synuclein vs. nonoverexpressing controls in the presence and absence of neurotoxic exposure. Results of these experiments should help to elucidate the mechanism of alpha-synuclein-induced neurodegeneration in familial and sporadic cases of human Parkinsonism. Transgenic mice overexpressing alpha-synuclein are also likely to be a suitable model for studying the mechanism of formation and role of Lewy body-like inclusions in nigrostriatal degeneration. Finally, findings could provide clues s to why the aging nigrostriatal system becomes more susceptible to neurodegeneration.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Research Project (R01)
Project #
5R01ES010442-03
Application #
6518180
Study Section
Special Emphasis Panel (ZRG1-BDCN-3 (01))
Program Officer
Lawler, Cindy P
Project Start
2000-04-01
Project End
2005-03-31
Budget Start
2002-04-01
Budget End
2003-03-31
Support Year
3
Fiscal Year
2002
Total Cost
$317,600
Indirect Cost
Name
Parkinson's Institute
Department
Type
DUNS #
614259935
City
Sunnyvale
State
CA
Country
United States
Zip Code
94085
Reaney, Stephen H; Johnston, Louisa C; Langston, William J et al. (2006) Comparison of the neurotoxic effects of proteasomal inhibitors in primary mesencephalic cultures. Exp Neurol 202:434-40
McCormack, A L; Atienza, J G; Langston, J W et al. (2006) Decreased susceptibility to oxidative stress underlies the resistance of specific dopaminergic cell populations to paraquat-induced degeneration. Neuroscience 141:929-37
Bonneh-Barkay, Dafna; Langston, William J; Di Monte, Donato A (2005) Toxicity of redox cycling pesticides in primary mesencephalic cultures. Antioxid Redox Signal 7:649-53
Bonneh-Barkay, Dafna; Reaney, Stephen H; Langston, William J et al. (2005) Redox cycling of the herbicide paraquat in microglial cultures. Brain Res Mol Brain Res 134:52-6
Purisai, Maya G; McCormack, Alison L; Langston, William J et al. (2005) Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiol Dis 20:898-906
McCormack, Alison L; Atienza, Jennifer G; Johnston, Louisa C et al. (2005) Role of oxidative stress in paraquat-induced dopaminergic cell degeneration. J Neurochem 93:1030-7
Manning-Bog, Amy B; McCormack, Alison L; Purisai, Maya G et al. (2003) Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 23:3095-9
Di Monte, Donato A (2003) The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet Neurol 2:531-8
McCormack, Alison L; Di Monte, Donato A (2003) Effects of L-dopa and other amino acids against paraquat-induced nigrostriatal degeneration. J Neurochem 85:82-6
Thiffault, Christine; Langston, J William; Di Monte, Donato A (2003) Cerebrospinal fluid 3,4-dihydroxyphenylacetic acid level after tolcapone administration as an indicator of nigrostriatal degeneration. Exp Neurol 183:173-9

Showing the most recent 10 out of 14 publications